Biogen Idec Names Adam M. Koppel as SVP and Chief Strategy Officer

  Biogen Idec Names Adam M. Koppel as SVP and Chief Strategy Officer

– Will Lead Corporate Strategy and Portfolio Management in Newly Created Role
                                      –

Business Wire

CAMBRIDGE, Mass. -- April 10, 2014

Biogen Idec (NASDAQ: BIIB) today announced the appointment of Adam M. Koppel,
M.D., Ph.D., as senior vice president and chief strategy officer, effective
May 15, 2014.

Dr. Koppel will be responsible for leading corporate strategy and portfolio
management, as well as ensuring that disease strategies clearly align with the
corporate strategy. He will report to George Scangos, Ph.D., chief executive
officer, and will be a member of the Biogen Idec management team.

“With his experience as a physician, scientist and executive, Adam will be
invaluable to Biogen Idec as we grow in size and complexity, bringing a unique
set of capabilities to bolster our position at the intersection of medicine,
science and economics,” said Dr. Scangos. “Adam is a respected biotechnology
investor and industry leader, and we are thrilled to have his insight and
vision to help guide our company and management team.”

Dr. Koppel will join Biogen Idec from Brookside Capital, the public equity
affiliate of Bain Capital, where he joined in 2003, serving as a managing
director since 2009. Prior to Brookside Capital, he was an associate principal
of the McKinsey Healthcare Practice. He holds Bachelor and Master of Arts
degrees in History and Science from Harvard College and earned an M.D. and
Ph.D. in Molecular Neurobiology from the University of Pennsylvania. He also
received an M.B.A. from the University of Pennsylvania’s Wharton School.

“Adam has been a great partner, and we wish him all the best as he leaves
public equity investing to pursue his passion for biotechnology at Biogen
Idec,” said Ted Pappendick, a managing director at Brookside Capital.

About Biogen Idec

Through cutting-edge science and medicine, Biogen Idec discovers, develops and
delivers to patients worldwide innovative therapies for the treatment of
neurodegenerative diseases, hemophilia and autoimmune disorders. Founded in
1978, Biogen Idec is the world’s oldest independent biotechnology company.
Patients worldwide benefit from its leading multiple sclerosis therapies. For
product labeling, press releases and additional information about the Company,
please visit www.biogenidec.com.

Contact:

MEDIA CONTACTS:
Biogen Idec
Jason Glashow, +1-781-464-3260
public.affairs@biogenidec.com
or
Biogen Idec
Kate Niazi-Sai, +1-781-464-3260
public.affairs@biogenidec.com
or
INVESTOR CONTACTS:
Biogen Idec
Benjamin Strain, +1-781-464-2442
IR@biogenidec.com
 
Press spacebar to pause and continue. Press esc to stop.